Ottobock SE & Co. KGaA is a medical device company headquartered in Germany, with R&D and manufacturing operations spanning 45 countries. The firm's technical work centers on prosthetics, orthotics, and exoskeletons, with a particular emphasis on microprocessor-controlled joints and human bionic systems. Its portfolio includes the C-Leg, the first microprocessor-controlled knee joint, and the C-Brace, an orthosis designed for controlled stair descent. The company's exoskeleton development is based in Emeryville, California.
Engineering challenges at Ottobock involve integrating sensor fusion and embedded control algorithms into wearable devices that must operate reliably across diverse biomechanical and environmental conditions. The hardware/software boundary is critical: actuators, joint mechanisms, and sensor arrays must interface with microprocessors running real-time gait analysis and adaptive control logic. The company's approximately 400 patient care centers worldwide provide a direct feedback loop between clinical deployment and iterative design refinement.
Ottobock was founded in 1919 and remains family-owned, employing nearly 9,300 people with annual revenue exceeding €1.6 billion. Manufacturing is concentrated in Duderstadt, Germany. The company's scope extends from R&D through clinical fitting and rehabilitation, covering the full lifecycle of mobility restoration devices. This integrated model allows engineers to work with direct field data from end users, informing constraints around weight, power consumption, durability, and user safety that define the engineering problem space.
